Company: SVREW
Filing Date: 2025-01-31
Form Type: 424B5
Source: 0001213900-25-008656
Chunk: 0

Company: SaverOne 2014 Ltd.
Filing Date: 2025-01-31
Form: 424B5
Chunk 0
---
Filed Pursuant to Rule 424(b)(5)

Registration No. 333-274458

(To Prospectus dated September 27, 2023)

<div align='center'>2,171,433 American Depositary Shares representing 195,428,970 Ordinary Shares

SaverOne 2014 Ltd.</div>

We are offering directly
to certain institutional investors pursuant to this prospectus supplement and the accompanying prospectus 195,428,970 ordinary shares
represented by 2,171,433 American Depositary Shares, or ADSs, at an offering price of $0.70 per ADS. Each ADS represents ninety (90)
of our ordinary shares, par value NIS 0.01 per share.

Our ADSs are listed on the Nasdaq
Capital Market, or Nasdaq, under the symbol “SVRE”. On January 29, 2025, the closing price of our ADSs on Nasdaq was $0.80
per ADS. Our ordinary shares also trade on the Tel Aviv Stock Exchange, or the TASE, under the symbol “SVRE”. On January
29, 2025, the last reported sale price of our ordinary shares on the TASE was NIS 0.035 or $0.0097 per share (based on the
exchange rate reported by the Bank of Israel on that date, which was NIS 3.6 = $1.00).

In addition, we are offering
warrants to purchase up to an aggregate of 4,342,866 ADS at an exercise price of $0.80 per ADS (the “Private Placement Warrants”)
in a concurrent private placement, with each Private Placement Warrant having the right to purchase one (1) ADS. The Private Placement
Warrants will become exercisable following the Company’s receipt of shareholder approval to increase the number of its authorized
ordinary shares pursuant to the Company’s amended and restated Articles of Association (the “Shareholder Approval Date”)
and will expire twenty-four (24) months from the Shareholder Approval Date. The Private Placement Warrants and the ordinary shares issuable
upon the exercise of such warrants (the “Warrant Shares”) are not being registered under the Securities Act of 1933, as amended
(the “Securities Act”), and are not being offered pursuant to this prospectus supplement and the accompanying prospectus.
They are being offered pursuant to an exemption from the registration requirements of the Securities Act provided in Section 4(a)(2)